

From: [Janice Castillo](#)  
To: [Gildner, Jean](#)  
Subject: RE: BLA 125586 Portola FDA Comments Re: Suffix  
Date: Wednesday, April 04, 2018 8:35:49 PM  
Attachments: [image007.png](#)

---

Jean,

Portola proposes an alternative list of suffixes below. However, should time constraints not allow for evaluation of these suffixes, we would chose [ZHZO](#) from the FDA list.

[ZXPA](#)

[PAXI](#)

[APXI](#)

[INHX](#)

[APXZ](#)

[Janice](#)

---

From: Gildner, Jean [mailto:Jean.Gildner@fda.hhs.gov]  
Sent: Wednesday, April 04, 2018 12:05 PM  
To: Janice Castillo  
Subject: BLA 125586 Portola FDA Comments Re: Suffix

Dear Janice,

Please see the following comments in regards to the list of suffixes you submitted to the FDA:

*FDA has determined that each of your proposed proper name suffixes are not devoid of meaning because each suffix either connotes the proprietary name, ANDEXXA, for this product (e.g., andx, anex, **annx, anxx, anxa, axxn, adxx**), **connotes the product's drug substance**, factor Xa, (e.g., andx, anex, annx, anxx, anxa, axxn, adxx), or directly references Portola and your product (e.g., pxxa). Thus, these proposed suffixes are each inconsistent with the principles described in our final guidance and unacceptable for inclusion in the proper name of this proposed product.*

*Because the proposed suffixes were found unacceptable, and given the time constraints, we **recommend that you use one of FDA's** randomly-generated, pre-screened suffixes for inclusion in the proper name of your product.*

*Please choose one of the following FDA-generated suffixes: zhzo, sjbg, knkq*

Please notify me of receipt of this email and suffix you wish to select. If you have any questions please feel free to contact me.

Sincerely, Jean

*Jean F. Gildner* MSHS, MT (ASCP)

**Regulatory Project Manager**  
**Center for Biologics Evaluation and Research**  
**Office of Tissues and Advanced Therapies**  
**U.S. Food and Drug Administration**  
Tel: 240-402-8296  
[jean.gildner@fda.hhs.gov](mailto:jean.gildner@fda.hhs.gov)



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.

This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message. If you are the intended recipient, please be advised that the content of this message is subject to access, review and disclosure by the sender's Email System Administrator.